Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 17

1.

Towards Inhibition of Vif-APOBEC3G Interaction: Which Protein to Target?

Cadima-Couto I, Goncalves J.

Adv Virol. 2010;2010:649315. doi: 10.1155/2010/649315. Epub 2010 Sep 21.

2.

Structural Features of Antiviral APOBEC3 Proteins are Linked to Their Functional Activities.

Kitamura S, Ode H, Iwatani Y.

Front Microbiol. 2011 Dec 21;2:258. doi: 10.3389/fmicb.2011.00258. eCollection 2011.

3.

APOBEC3G complexes decrease human immunodeficiency virus type 1 production.

Martin KL, Johnson M, D'Aquila RT.

J Virol. 2011 Sep;85(18):9314-26. doi: 10.1128/JVI.00273-11. Epub 2011 Jul 13. Erratum in: J Virol. 2012 Aug;86(16):8916.

4.

HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.

Cadima-Couto I, Saraiva N, Santos AC, Goncalves J.

J Neuroimmune Pharmacol. 2011 Jun;6(2):296-307. doi: 10.1007/s11481-011-9258-7. Epub 2011 Jan 29.

PMID:
21279453
5.

Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Hultquist JF, Harris RS.

Future Virol. 2009 Nov 1;4(6):605.

6.

Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.

Albin JS, Harris RS.

Expert Rev Mol Med. 2010 Jan 22;12:e4. doi: 10.1017/S1462399409001343. Review.

7.

Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis.

Lavens D, Peelman F, Van der Heyden J, Uyttendaele I, Catteeuw D, Verhee A, Van Schoubroeck B, Kurth J, Hallenberger S, Clayton R, Tavernier J.

Nucleic Acids Res. 2010 Apr;38(6):1902-12. doi: 10.1093/nar/gkp1154. Epub 2009 Dec 16.

8.

Host restriction of HIV-1 by APOBEC3 and viral evasion through Vif.

Niewiadomska AM, Yu XF.

Curr Top Microbiol Immunol. 2009;339:1-25. doi: 10.1007/978-3-642-02175-6_1. Review.

PMID:
20012521
9.

Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.

Smith JL, Bu W, Burdick RC, Pathak VK.

Trends Pharmacol Sci. 2009 Dec;30(12):638-46. doi: 10.1016/j.tips.2009.09.006. Review.

10.

Interactions in vivo between the Vif protein of HIV-1 and the precursor (Pr55(GAG)) of the virion nucleocapsid proteins.

Syed F, McCrae MA.

Arch Virol. 2009;154(11):1797-805. doi: 10.1007/s00705-009-0520-8. Epub 2009 Oct 14.

PMID:
19826902
11.

Antiviral roles of APOBEC proteins against HIV-1 and suppression by Vif.

Romani B, Engelbrecht S, Glashoff RH.

Arch Virol. 2009;154(10):1579-88. doi: 10.1007/s00705-009-0481-y. Epub 2009 Aug 12. Review.

PMID:
19669862
12.

Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.

Henriet S, Mercenne G, Bernacchi S, Paillart JC, Marquet R.

Microbiol Mol Biol Rev. 2009 Jun;73(2):211-32. doi: 10.1128/MMBR.00040-08. Review.

13.

Accessories to the crime: recent advances in HIV accessory protein biology.

Gramberg T, Sunseri N, Landau NR.

Curr HIV/AIDS Rep. 2009 Feb;6(1):36-42. Review.

14.

APOBEC proteins and intrinsic resistance to HIV-1 infection.

Malim MH.

Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):675-87. doi: 10.1098/rstb.2008.0185. Review.

15.

Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.

Russell RA, Smith J, Barr R, Bhattacharyya D, Pathak VK.

J Virol. 2009 Feb;83(4):1992-2003. doi: 10.1128/JVI.01621-08. Epub 2008 Nov 26.

16.

APOBEC3G: an intracellular centurion.

Chiu YL, Greene WC.

Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):689-703. doi: 10.1098/rstb.2008.0193. Review.

Supplemental Content

Support Center